Arcus and Summit Team Up to Test Novel Kidney Cancer Combo, Data by Mid-2027
RCUS has more than doubled off its 52-week low of $8.84.
Summary
Arcus and Summit are launching a clinical trial collaboration to combine Arcus's HIF-2α inhibitor casdatifan with Summit's PD-1/VEGF bispecific ivonescimab in clear cell renal cell carcinoma, including first-line metastatic disease. The study will add a new cohort to Arcus's ongoing ARC-20 platform trial, with Summit supplying ivonescimab and Arcus sponsoring and conducting the study; both companies share costs and retain rights to their own molecules. Initial data is expected by mid-2027. This follows Arcus's Q1 revenue decline and recent trial discontinuations, making pipeline advancement critical. The collaboration targets a large market—kidney cancer is a top-10 U.S. cancer with ~80,450 new cases expected in 2026—and a high unmet need in metastatic disease where five-year survival is only 19%. For Summit, it expands ivonescimab's reach into a new indication with a differentiated combination.
At the time of this announcement, RCUS was trading at $30.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.84 to $31.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.